Editorial for Special Issue “Alternatives to Antibiotics: Bacteriocins and Antimicrobial Peptides”

Neves, João V.

doi:10.3390/antibiotics11070860

Cited by 3 publications

(3 citation statements)

References 12 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, extensive use of antibiotics has led to the emergence of antibiotic resistance and subsequent multidrug-resistant pathogens (MDRP), which diminished the effectiveness of existing antibiotics [1]. They are not only becoming increasingly problematic for human health and other elds crucial for human survival [2] but also increasing the global economic burden. According to a study led by Jim O'Neill, drug-resistant diseases cause more than 700,000 deaths annually [3].…”

Section: Introductionmentioning

confidence: 99%

“…( ) They have stronger inhibitory effectory yet display no toxicity toward eukaryotic cells [11]. Generally, antibiotics need a micromolar level for their activity, but bacteriocins act speci cally to target bacteria only at the nanomolar level [10] ( ) They show a lower propensity to develop resistance [2] and will not cause environmental pollution. On the one hand, bacteriocins act through quick pore formation on the target cell membrane at extremely low concentrations; on the other hand, they can be degraded easily in our bodies and other environments because of their proteinaceous nature [11].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Garvicin-SHAMU-LG6, A Novel Bacteriocin from Lactococcus garvieae That Exert Broad Antimicrobial Activity Against Drug-Resistant Pathogens

Weng,

Leng,

Gao

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Accelerating growth and global expansion of antimicrobial resistance has deepened the demand for discovery of novel antimicrobial agents. Bacteriocins have attracted increasing interest because of their high efficiency, low toxicity and being not easy to cause drug resistance. This study aims to investigate a novel broad-spectrum bacteriocin, contributing to the pharmaceutical fields. Results From a human urine specimen, we isolated a strain thatproduced a novel broad-spectrum bacteriocin, which was identified as Lactococcus garvieae SHAMU-LG6. The bacteriocin, termed garvicin-SHAMU-LG6. The Oxford cup methoddemonstrated it could inhibit the growth of various clinically pathogenic and multidrug-resistant pathogens (MDRP). Whole genome sequencing analysis found a putative gene cluster, that shared 10% similarity with the most similar known bacteriocin cluster. In addition, the cell-free supernatant (CFS) of L. garvieae SHAMU-LG6 exerts antimicrobial activity against S. aureus by disrupting the integrity of bacterial cells. Furthermore, garvicin-SHAMU-LG6 was preliminary purified from the CFS of L. garvieae SHAMU-LG6. Its crude extraction showed good pH (pH 3 to 11) and heat stability (30℃ to 121℃) and resistance to the digestion of chymotrypsin, trypsin, proteinase K, and bromelain. Conclusions All these studies suggested that garvicin-SHAMU-LG6 has the potential to be used as a therapeutic drug against pathogenic bacteria as well as MDRP in the food and pharmaceutical fields.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Garvicin-SHAMU-LG6, A Novel Bacteriocin from Lactococcus garvieae That Exert Broad Antimicrobial Activity Against Drug-Resistant Pathogens

Weng,

Leng,

Gao

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…The presence of virulence factors, resistance against antibiotics and biogenic amine production was evaluated [13]. Here, the evaluation of enterocin production by those enterococci was carried out, which can be of interest as alternatives to antibiotics due to the increased the number of resistances in clinical and commensal bacteria [14][15][16]. The use of bacteriocins as therapeutic agents as well as part of a multiple hurdle approach with antibiotics have been recently explored as viable alternative [17].…”

Section: Introductionmentioning

confidence: 99%

Enterocins Produced by Enterococci Isolated from Breast-Fed Infants: Antilisterial Potential

Landete,

Montiel,

Rodríguez-Mínguez

et al. 2023

Preprint

View full text Add to dashboard Cite

Enterocins are bacteriocins synthesized by Enterococcus strains that show an interesting antimi-crobial effectiveness against foodborne pathogens such as Listeria monocytogenes. The objectives of this study were identify and analyze the expression of enterocin genes of Enterococcus isolated from breast-fed infants and evaluate the ability to inhibit three human isolates of virulent Lis-teria monocytogenes, as well as some probiotic bacteria. The susceptibility of the strains of L. mon-ocytogenes to fifteen antibiotics was tested, detecting resistance to cefoxitin (constitutive-ly resistant), oxacillin and clindamycin. Production of enterocins A, B and P were observed in Enterococcus faecium isolates, and enterocin AS-48 in an Enterococcus faecalis isolate. AS-48 showed antilisterial activity by itself, while the joint action of enterocins A and B, or B and P was neces-sary for inhibiting L. monocytogenes, demonstrating a synergistic effect of those combinations. The presence of multiple enterocin genes does not assured the inhibition of L. monocytogenes strains. However, the expression of multiple enterocin genes showed a good correlation with the inhibition capacity of these strains. Furthermore the potential beneficial strains of lactobacil-li and bifidobacteria examined were not inhibited by any of the enterocins produced individu-ally or in combination, with the exception of Bifidobacterium longum BB536, which was inhibited by enterocin AS-48 and the joint production of enterocins A and B or B and P. The enterocins studied here could be candidates for developing alternative treatments against antibi-otic-resistant bacterial infections. Moreover, these selected enterocin-producing E. faecium strains isolated from breast-fed infants could be used as probiotic strains due to their antilisterial effect as well as the absence of virulence factors.

show abstract

Enterocins Produced by Enterococci Isolated from Breast-Fed Infants: Antilisterial Potential

Landete,

Montiel,

Rodríguez-Mínguez

et al. 2024

Children

View full text Add to dashboard Cite

Enterocins are bacteriocins synthesized by Enterococcus strains that show an interesting antimicrobial effectiveness against foodborne pathogens such as Listeria monocytogenes. The objectives of this study were to identify and analyze the expression of enterocin genes of Enterococcus isolated from breast-fed infants and evaluate their ability to inhibit three human isolates of virulent L. monocytogenes, as well as some probiotic bacteria. The susceptibility of the strains of L. monocytogenes to fifteen antibiotics was tested, detecting their resistance to cefoxitin (constitutively resistant), oxacillin, and clindamycin. The production of enterocins A, B, and P was observed in Enterococcus faecium isolates, while enterocin AS-48 was detected in an Enterococcus faecalis isolate. AS-48 showed antilisterial activity by itself, while the joint action of enterocins A and B or B and P was necessary for inhibiting L. monocytogenes, demonstrating the synergistic effect of those combinations. The presence of multiple enterocin genes does not assure the inhibition of L. monocytogenes strains. However, the expression of multiple enterocin genes showed a good correlation with the inhibition capacity of these strains. Furthermore, the potential beneficial strains of lactobacilli and bifidobacteria examined were not inhibited by any of the enterocins produced individually or in combination, with the exception of Bifidobacterium longum BB536, which was inhibited by enterocin AS-48 and the joint production of enterocins A and B or B and P. The enterocins studied here could be candidates for developing alternative treatments against antibiotic-resistant bacterial infections. Moreover, these selected enterocin-producing E. faecium strains isolated from breast-fed infants could be used as probiotic strains due to their antilisterial effect, as well as the absence of virulence factors.

show abstract

Editorial for Special Issue “Alternatives to Antibiotics: Bacteriocins and Antimicrobial Peptides”

Abstract: The discovery of penicillin in 1928 by Sir Alexander Fleming, and its later introduction as an antibiotic in the early 1940s, was a gamechanger for the entire medical field [...]

Cited by 3 publications

References 12 publications

Garvicin-SHAMU-LG6, A Novel Bacteriocin from Lactococcus garvieae That Exert Broad Antimicrobial Activity Against Drug-Resistant Pathogens

Garvicin-SHAMU-LG6, A Novel Bacteriocin from Lactococcus garvieae That Exert Broad Antimicrobial Activity Against Drug-Resistant Pathogens

Enterocins Produced by Enterococci Isolated from Breast-Fed Infants: Antilisterial Potential

Enterocins Produced by Enterococci Isolated from Breast-Fed Infants: Antilisterial Potential

Contact Info

Product

Resources

About